Enopace Biomedical is developing a minimally invasive, implantable endovascular stimulator that reduces left ventricle workload and improves the systolic/diastolic ratio.

 

Fibro Control is developing a minimally invasive device for temporary occlusion of the uterine arteries to treat uterine fibroids.

 

GluSense is developing an accurate, long-term, minimally invasive, implantable, continuous glucose sensor for diabetes patients.

 

Maxillent is developing a breakthrough solution to a key problem in the field of dental implants.

 

Nano-Retina is developing an artificial retinal prosthesis based on a proprietary nano-technology configuration for sight restoration. The device is being developed in collaboration with a leading nano-tech lab in Texas.

 

PharmaLight is developing an ocular drug delivery platform that safely and effectively administers therapeutics, including macro molecules, to the posterior segment of the eye.

 

ProstaPlant is developing a transurethral implant for symptomatic Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS).

 

Slender Medical is developing a novel treatment for subdermal tissues using non-invasive high intensity focused ultrasound (HIFU). Treatment indications include aesthetic fat reduction, specifically designed for small areas such as the chin, calf, ankle, arms and anterior thigh, as well as treatment of lipomas.

 

Vascular Dynamics is developing an implantable stent-like device to treat hypertension by correction of inflexible arterial motion.